
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is a global biotechnology company with a strong portfolio in virology and infectious diseases, and a growing presence in the oncology market. The company's acquisition of Pharmasset brings rights to hepatitis C drug Sovaldi, which, along with newer combination therapies, remains a standard of care for the disease. Gilead's strong HIV franchise, led by drugs like Biktarvy and Descovy, and its expanding portfolio of oncology drugs, such as Yescarta, Tecartus, and Trodelvy, position the company for continued growth. Additionally, Gilead's commitment to diversity and sustainability efforts further support its long-term outlook.
Bears say
Gilead Sciences is facing potential competition in its HIV product portfolio as newer drugs, such as Biktarvy and Descovy, may face challenges from longer-acting combo regimens in the future. Additionally, the company's PrEP drug, Yeztugo, may require a more intensive loading regimen, limiting its use. Despite strong financial performance in the first quarter of 2026, Gilead's guidance for the full year reflects a degree of conservatism, likely due to potential pricing pressures from drug pricing agreements and ACA changes. The company's pipeline, while diverse, may face competition from new treatments in areas such as inflammatory diseases and oncology, potentially impacting future growth.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares